Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65years patients with de novo acute myeloid leukemia

• Published in: American journal of hematology Vol. 98; no. 5; pp. 760 - 769
• Main Authors: Min‐Yen Lo, Xavier Cheng‐Hong Tsai, Chien‐Chin Lin, Feng‐Ming Tien, Yuan‐Yeh Kuo, Wan‐Hsuan Lee, Yen‐Ling Peng, Ming‐Chih Liu, Mei‐Hsuan Tseng, Cheng‐An Hsu, Jui‐Che Chen, Liang‐In Lin, Hsun‐I Sun, Yi‐Kuang Chuang, Bor‐Sheng Ko, Jih‐Luh Tang, Yao, Ming, Wen‐Chien Chou, Hsin‐An Hou, Hwei‐Fang Tien
• Format: Journal Article
• Language: English
• Published: New York Wiley Subscription Services, Inc 01-05-2023
• Subjects: Acute myeloid leukemia; Allografts; Chemotherapy; Hematology; Janus kinase 2; Karyotypes; Leukemia; Mutation; Prediction models; Remission; Remission (Medicine); Risk groups; Runx1 protein; Transplantation
• ISSN: 0361-8609; 1096-8652
• DOI: 10.1002/ajh.26892

The European LeukemiaNet (ELN) recently proposed a revised recommendation for the diagnosis and management of acute myeloid leukemia (AML) in adults, recognized as ELN‐2022. However, validation in a large real‐world cohort remains lacking. In this study, we aimed to validate the prognostic relevance of the ELN‐2022 in a cohort of 809 de novo, non‐M3, younger (ages 18–65 years) AML patients receiving standard chemotherapy. The risk categories of 106 (13.1%) patients were reclassified from that determined using ELN‐2017 to that determined using ELN‐2022. The ELN‐2022 effectively helped distinguish patients as favorable, intermediate, and adverse risk groups in terms of remission rates and survival. Among patients who achieved first complete remission (CR1), allogeneic transplantation was beneficial for those in the intermediate risk group, but not for those in the favorable or adverse risk groups. We further refined the ELN‐2022 system by re‐categorizing AML patients with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 with KIThigh, JAK2 or FLT3‐ITDhigh mutations into the intermediate risk subset, AML patients with t(7;11)(p15;p15)/NUP98::HOXA9 and AML patients with co‐mutated DNMT3A and FLT3‐ITD into the adverse risk subsets, and AML patients with complex or monosomal karyotypes, inv (3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2,MECOM(EVI1) or TP53 mutation into the very adverse risk subset. The refined ELN‐2022 system performed effectively to distinguish patients as favorable, intermediate, adverse, and very adverse risk groups. In conclusion, the ELN‐2022 helped distinguish younger, intensively treated patients into three groups with distinct outcomes; the proposed refinement of ELN‐2022 may further improve risk stratification among AML patients. Prospective validation of the new predictive model is necessary.